Gemcitabine nano-prodrug reprograms intratumoral metabolism and alleviates immunosuppression for hepatocellular carcinoma therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Cancer Research and Treatments · Epigenetics and DNA Methylation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Medical therapies for hepatocellular carcinoma: a critical view of the evidence10.1038/nrgastro.2012.199 ↗
2. Hepatocellular carcinoma10.1038/s41572-020-00240-3 ↗
3. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer10.3390/cells10071715 ↗
4. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis10.1136/jitc-2020-001367 ↗
5. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial10.1093/jnci/dju413 ↗
6. Targeting mTORC2/HDAC3 inhibits stemness of liver cancer cells against glutamine starvation
7. Oxidative metabolism drives immortalization of neural stem cells during tumorigenesis10.1016/j.cell.2020.07.039 ↗
8. The emerging hallmarks of cancer metabolism10.1016/j.cmet.2015.12.006 ↗
9. Metabolic modulation of the tumor microenvironment leads to multiple checkpoint inhibition and immune cell infiltration10.1021/acsnano.9b10037 ↗
10. A unique subset of glycolytic tumour-propagating cells drives squamous cell carcinoma10.1038/s42255-021-00350-6 ↗
11. Otto Warburg's contributions to current concepts of cancer metabolism10.1038/nrc3038 ↗
12. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs10.1158/0008-5472.CAN-14-3745 ↗
13. Dual tumor microenvironment remodeling by glucose-contained radical copolymer for mri-guided photoimmunotherapy10.1002/adma.202107674 ↗
14. Self-blockade of PD-L1 with bacteria-derived outer-membrane vesicle for enhanced cancer immunotherapy10.1002/adma.202106307 ↗
15. GSH-responsive nanoprodrug to inhibit glycolysis and alleviate immunosuppression for cancer therapy10.1021/acs.nanolett.1c03089 ↗
16. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer
17. Metal-phenolic network-enabled lactic acid consumption reverses immunosuppressive tumor microenvironment for sonodynamic therapy10.1021/acsnano.1c08026 ↗
18. Glutamine antagonist synergizes with electrodynamic therapy to induce tumor regression and systemic antitumor immunity10.1021/acsnano.1c08544 ↗
19. Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes10.1016/j.biomaterials.2021.120711 ↗
20. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid10.1038/s41586-020-03045-2 ↗
21. Starvation strategy for amplification of tumor-specific chemotherapy
22. Molecular basis of ligand recognition and transport by glucose transporters10.1038/nature14655 ↗
23. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer10.1038/s41467-020-18020-8 ↗
24. Carrier-free immunotherapeutic nano-booster with dual synergistic effects based on glutaminase inhibition combined with photodynamic therapy10.1021/acsnano.2c11037 ↗
25. Biomimetic nanoplatform loading type I aggregation-induced emission photosensitizer and glutamine blockade to regulate nutrient partitioning for enhancing antitumor immunotherapy10.1021/acsnano.2c02605 ↗
26. Metabolism of immune cells in cancer10.1038/s41568-020-0273-y ↗
27. Targeting metabolism to regulate immune responses in autoimmunity and cancer10.1038/s41573-019-0032-5 ↗
28. Acetate promotes T cell effector function during glucose restriction10.1016/j.celrep.2019.04.022 ↗
29. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells10.1172/JCI131859 ↗
30. From Krebs to clinic: glutamine metabolism to cancer therapy10.1038/nrc.2016.71 ↗
31. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer10.1038/onc.2015.381 ↗
32. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models10.1038/nm.4464 ↗
33. Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion10.1016/j.cmet.2020.11.020 ↗
34. Strategy disrupts energy metabolism and alleviates immunosuppression for cancer therapy10.1021/acs.nanolett.2c02475 ↗
35. Interference of glucose bioavailability of tumor by engineered biohybrids for potentiating targeting and uptake of antitumor nanodrugs10.1021/acs.nanolett.2c03608 ↗
36. Tumor-specific chemotherapy by nanomedicine-enabled differential stress sensitization10.1002/anie.202002306 ↗
37. Mitochondrial dysfunction and antioxidation dyshomeostasis-enhanced tumor starvation synergistic chemotherapy achieved using a metal-organic framework-based nano-enzyme reactor10.1021/acsami.1c18654 ↗
38. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling10.1186/s13046-020-01579-x ↗
39. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies10.1158/1078-0432.CCR-14-1019 ↗
40. Phosphorylation of PDHA by AMPK drives TCA Cycle to promote cancer metastasis10.1016/j.molcel.2020.09.018 ↗
41. Immunomodulation-enhanced nanozyme-based tumor catalytic therapy10.1002/adma.202003563 ↗
42. Dual inhibitions on glucose/glutamine metabolisms for nontoxic pancreatic cancer therapy10.1021/acsami.2c00111 ↗